Drug · DIN 02516918
RETEVMO
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since November 6, 2025; first marketed January 21, 2022.
- Drug Identification Number (DIN)
- 02516918
- Company (DIN owner)
- Eli Lilly Canada IncToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Selpercatinib L01EX22
- Class
- Human
- Record last updated
- March 11, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| SELPERCATINIB | 40 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- November 6, 2025: NOC 36338New Drug Submission (NDS) · Change in product ownership
- June 15, 2021: NOC 26077New Drug Submission (NDS)
Other DINs named RETEVMO
- DIN 02516926 · Marketed
- DIN 02565676 · Marketed
- DIN 02565668 · Approved